Please login to the form below
BACE inhibitor
This page shows the latest BACE inhibitor news and features for those working in and with pharma, biotech and healthcare.
Merck acquires pre-clinical biotech Calporta for up to $576m
Merck, among many big pharma players, has had its fair share of failure in the neurodegenerative research area – its lead BACE inhibitor verubecestat failed to show a clinical effect in
Latest news
-
Biogen and Eisai drop Alzheimer’s drug elenbecestat
Latest blow in string of failures for BACE inhibitor category. In a potential final blow to the BACE inhibitor treatment category, Biogen and Eisai have discontinued trials of elenbecestat after the ... The sadly predictable pattern of the BACE
-
Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms
Novartis and Amgen researchers were well aware of these problems seen in earlier BACE inhibitor trials, but had not detected them in their own early trials. ... The loss of CNP520 leaves just one major BACE inhibitor standing – Eisai and Biogen’s
-
Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022
The additional study could also include an arm combining BAN2401 with Eisai’s BACE inhibitor elenbecestat, a drug class that has also seen a string of failures in late-stage testing ... BACE inhibitors are designed to an enzyme involved in the
-
Eisai to tackle dementia in new US research facility
Merck &Co has also seen failure with its BACE1 inhibitor verubecestat, which also led to the drug’s abandonment. ... However Eisai, which also has a BACE inhibitor elenbecestat in late-stage testing, has several dementia candidates in its pipeline, and
-
Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit votes loom
Today’s biggest pharma news is more grim tidings from the field of Alzheimer’s research – AZ and Lilly have conceded defeat on their BACE inhibitor. ... Off BACE: AZ/Lilly drop Alzheimer’s drug lanabecestat.
Biogen and Eisai drop Alzheimer’s drug elenbecestat
Amgen and Novartis abandon Alzheimer’s drug after worsening symptoms
Biogen, Eisai cue up BAN2401 readout in Alzheimer’s in 2022
Eisai to tackle dementia in new US research facility
Daily Brief: PRIME status for vaccine, NHS urged to adopt automation, Brexit votes loom
More from news
Approximately 3 fully matching, plus 22 partially matching documents found.
Latest Intelligence
-
Deal Watch table for September 2014
525. AstraZeneca / Lilly. Licence and collaboration. Oral BACE inhibitor in phase I for Alzheimer's disease. ... TGR-1202 an oral P13K-delta inhibitor in phase II for haematological malignancies.
-
Pharma deals during September 2014
Rhizen to change their deal from a 50/50 joint venture to a global (excluding India) licence. The product, an oral PK13 delta inhibitor appears to have completed phase 2 the ... AstraZeneca and Lilly have announced a joint development and
-
Eisai: Bucking the trend with R&D growth
BACE inhibitor E2609.
Deal Watch table for September 2014
Pharma deals during September 2014
Eisai: Bucking the trend with R&D growth
More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- Account Director, Medical & Brand Communications, London/ SE...
-
Highly competitive salary
- Medical Writers (All levels) Editorial / Scientific Leads & ...
-
Highly Competitive Remuneration packages
- Editorial Director - UK, , EUROPE, REMOTE.
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Management Trainer, Medical Communications, Londo...
-
Highly competitive salary
- Medical Writer, Women’s health, Medical Communications agency, h...
-
Highly competitive salary
- Freelance Scientific Director, Medical Communications, London/ S...
-
Highly competitive salary
- Home Working Medical Copy Writer & Senior Medical Copy Write...
-
Highly Competitive Salary, Bonus &Benefits
- Senior Account Director, Medical & Brand Communications, Lon...
-
Highly competitive salary
- One dose of AZ’s COVID-19 vaccine ‘highly effective’ against severe disease from variants
- AstraZeneca’s Imfinzi provides sustained survival benefit for lung cancer patients
- EU “still interested” in Valneva COVID vaccine despite UK snub
- US demand for COVID-19 antibody treatments rising fast
- First oral antiviral drug for COVID-19 reviewed by Health Canada
- Havas Life Medicom and ARK lead at 2021 PM Society Digital Awards
- COVID-19 Pfizer/BioNTech booster approved by FDA and CDC
- AstraZeneca invests in RNA tech platform
- Market shaping demands behaviour change
- Healthcare Access and Payment Reform in the US
- Advancing Drug Discovery with Structured and Intelligent Data
- Fishawack Health appoints Elizabeth Landon in the newly created Chief People Officer role
- David Hunt launches independent agency The Considered
- EU “still interested” in Valneva COVID vaccine despite UK snub
- Oxford PharmaGenesis wins Communiqué Medical Affairs Agency of the Year award at Communiqué 2021
- FDA’s director and deputy director of its Office of Vaccines Research & Review resign
- $47.5m research centre to seek genetic insights into disease
- New data from Moderna supports COVID boosters
PMHub
11 London
The biggest problems facing humanity today are health-related, and the health of people, animals and our planet are inextricably linked. ...
Latest intelligence
- Robust Review: COVID19 Assessment
- See how our client utilized Rapid Payer Response (RPR) to stay informed and gain continuous insights during the recent global pandemic (COVID19)...
- All change – how untangling human behaviour can encourage better health
- Driving better patient outcomes through clear, achievable practical steps that are underpinned by transparent evidence...
- Health literacy in the time of COVID-19
- In a time when much of the media’s focus is on the ongoing COVID-19 pandemic and the differences in vaccination rates between various regions, countries, and socioeconomic groups, improving health...
